Semaglutide: from study to decision to citation

Two registered trials that compare semaglutide, one against placebo and one head to head with tirzepatide, with their exact results and the U.S. decision for the Wegovy product.

Also searched as Wegovy, Ozempic, Rybelsus. AI-assisted source verification, checked 2026-11-13. Human review: none recorded. Version 1.0.0 of this journey is frozen at its API address.

  1. 1 Registered study
  2. 2 Exact result
  3. 3 Regulatory decision
  4. 4 Copy the citation

1. Registered study

The original registry record is the primary source for what was planned, who was enrolled and what was posted.

2. Exact result

STEP 1 (double-blind)

Population
1,961 adults with BMI 30 or more (27 or more with a weight-related condition), without diabetes
Comparison
Semaglutide 2.4 mg vs placebo, plus lifestyle intervention
Comparator
Placebo plus lifestyle intervention (2:1 randomization)
Endpoint
Percent change in body weight and weight reduction of at least 5% (coprimary)
Time point
68 weeks
Result
-14.9% with semaglutide vs -2.4% with placebo; estimated difference -12.4 percentage points
Uncertainty
Difference 95% CI -13.4 to -11.5
Source
PMID 33567185, doi:10.1056/NEJMoa2032183, registry NCT03548935
Where each number sits (matched)
Flagship Weight Management 1.3.0: open "Verify this result" on the result for the table, figure or text location of each displayed number.

Limits of this record

  • Treatment-policy primary estimand: effects regardless of adherence and of other anti-obesity treatment or rescue (the publication abstract's wording is "regardless of treatment discontinuation or rescue interventions"). The displayed difference of -12.4 points (95% CI -13.4 to -11.5) matches the registry's ANCOVA treatment difference, the method the plan specifies for this estimand. The arm values -14.9% and -2.4% are verified in the abstract only; the registry posts different, observed means.

Open “Verify this result” for locators, automated checks and the list of what is unverified.

SURMOUNT-5 (phase 3b, open-label)

Population
751 adults with obesity, without type 2 diabetes
Comparison
Tirzepatide vs semaglutide
Comparator
Maximum tolerated dose: tirzepatide 10 or 15 mg vs semaglutide 1.7 or 2.4 mg, once weekly
Endpoint
Percent change in weight from baseline to week 72
Time point
72 weeks
Result
-20.2% with tirzepatide vs -13.7% with semaglutide (least-squares means; P<0.001)
Uncertainty
95% CI -21.4 to -19.1 (tirzepatide); -14.9 to -12.6 (semaglutide)
Source
PMID 40353578, doi:10.1056/NEJMoa2416394, registry NCT05822830
Where each number sits (matched)
Flagship Weight Management 1.3.0: open "Verify this result" on the result for the table, figure or text location of each displayed number.

Limits of this record

  • Modified treatment-regimen estimand (the plan's primary): participants included regardless of treatment discontinuation or other anti-obesity medication, except switching to the other study drug. The displayed -20.2% and -13.7% match the registry's ANCOVA result over the full analysis set, which is the method the plan specifies for this estimand (§4.3.1); the publication abstract does not name the estimand, so this is verified by method, not by an explicit label.

Open “Verify this result” for locators, automated checks and the list of what is unverified.

3. Regulatory decision

A regulator’s decision about one product. It is context, not scientific evidence, and does not transfer to other products or conditions.

FDA, United States: WEGOVY (semaglutide) injection, NDA 215256

Indication
Chronic weight management. FDA's Drugs@FDA record lists the original approval as a new indication submitted as a distinct NDA. The current indications are in the linked prescribing information; WPF's automated check could not retrieve the June 2026 label from FDA (HTTP 404 to a non-browser request), so they are not restated here.
Action type
New drug application approval (original), with later labeling supplements
Decision date
2021-06-04
Date checked
2026-11-13
Official source
openFDA Drugs@FDA record for NDA215256 (submission ORIG-1, status AP, 2021-06-04; latest efficacy supplement 2026-03-19) · Open the same record on Drugs@FDA (a web page; the link above is the machine-readable record WPF read)
Limits
Other semaglutide products (Ozempic, Rybelsus) are separate applications with their own decisions and are not covered by this record. Approval is regulatory context, not evidence that a trial result applies to a given person.

No published WPF record for: European Union (other than the profile's EPAR link); United Kingdom; Canada; Australia; Japan; China. That says only that WPF has published none, not that no regulatory action exists. See the profile’s regulatory section or the regulatory matrix for Semaglutide, which shows every jurisdiction and where WPF has no published review.

Film

Semaglutide: one molecule, different medicines

4. Copy the citation

Each citation names the release version and a versioned record address. If the evidence changes, the old address still returns the version you cited and links to the update.

STEP 1 (double-blind)

STEP 1 (double-blind). Semaglutide 2.4 mg vs placebo, plus lifestyle intervention. Primary source: https://doi.org/10.1056/NEJMoa2032183 (PMID 33567185; NCT03548935). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.3.0, result step-1-weight-68w.

Page:
https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#step-1-weight-68w

Versioned record:
https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=step-1-weight-68w

SURMOUNT-5 (phase 3b, open-label)

SURMOUNT-5 (phase 3b, open-label). Tirzepatide vs semaglutide. Primary source: https://doi.org/10.1056/NEJMoa2416394 (PMID 40353578; NCT05822830). Cited from World Peptide Foundation, WPF Flagship Weight Management, version 1.3.0, result surmount-5-weight-72w.

Page:
https://www.worldpeptidefoundation.org/research/flagship/compare/weight-management#surmount-5-weight-72w

Versioned record:
https://www.worldpeptidefoundation.org/api/research/flagship/weight-management?version=1.3.0&resultId=surmount-5-weight-72w